The only update for patients with stage IV NSCLC without driver alterations is that patients who have HER2-overexpressing (IHC 3+) disease and good performance status can receive trastuzumab ...

In patients with locally advanced non–small cell lung cancer (NSCLC), combining PET with invasive staging methods led to “relevant changes” of target volumes in 10% of cases, researchers ...

Emerging data suggest that SBRT may be comparable with surgery for definitive treatment of stage I NSCLC in certain patients. When is one approach preferred and in whom?